arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Revolution Medicines, Inc.

RVMD
$190.78 ▼ -2.23 (-1.16%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
32 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Revolution Medicines, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $40.2B
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -15.3%
FCF / Share $-1.85
Trailing P/E
Price / Book 15.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-453.82M
↓ -112.6%
Operating Margin Operating profit as % of sales
-402.5%
↓ -9.0%
FCF / Share Free cash flow per share
$-1.85
↓ -2.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters